UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION WASHINGTON, D.C. 20580



Office of the Secretary Scott Spielberg

January 25, 2010

Re: In the Matter of Pfizer Inc. and Wyeth, Docket No. C-4267

Dear Mr. Spielberg:

Thank you for your comments regarding the proposed consent order accepted by the Federal Trade Commission for public comment in the above-captioned matter. Your letter indicates that you are concerned that the merger should be thoroughly reviewed.

antitrust-related issues. You raised a number of concerns about product liability claims relating to Wyeth's fen-phen, including the fairness of the resolution of those claims. The Commission neither has the authority to investigate these issues nor could it block the merger of Pfizer and Wyeth on that basis.

In investigating this merger, the Commission considered whether the merger would lead to higher prescription drug prices or less innovation to develop new pharmaceutical products. The **Gantheipsiopo'sest traps** action may have on any human health

market. The Commission concluded that the transaction does not raise anticompetitive concerns in any human health product market.

For these reasons, the Commission has determined that the public interest would best be served by issuing the De